Astra Tech sale options ‘still under consideration’

Astra Tech's parent company AstraZeneca is still evaluating its potential options over the possible sale of the dental implants manufacturer.

A spokeswoman for the healthcare company confirmed to the Telegraph that it remains engaged in assessing the best-value options for the sale, with no final decision to be made until this review has been completed.

The future of the business – which offers products such as Atlantis abutments and OsseoSpeed TX Profile implants – is being reviewed due to AstraZeneca's desire to increase its focus on core pharmaceutical operations.

According to the Telegraph, private equity firms such as PAI Partners, Cinven, Bridgepoint and EQT are said to be considering making bids for part or all of Astra Tech.

It is thought that the sale of the unit would raise around 1.2 billion pounds for AstraZeneca.

The company's representative said: "The decision will be based on … the value we can realise compared to the value we see by continuing to run the business ourselves."